Dyadic will use the data to maximize the utility of its Host Technology for the organism, also known as C1. The company said the Host Technology business "forms a cornerstone" of its Enzymes and Biosciences units.
Financial details of the agreement were not disclosed.
To date, Dyadic scientists have characterized approximately 30 C1 genes, the company said. With Agencourt's help, the firm "expect[s] to identify up to 12,000 genes" in the C1 genome, including genes for potential new protein and enzyme products.
Agencourt, an NHGRI-designated Large Scale Sequencing Center, will conduct all phases of the sequencing project, including construction of multiple libraries, high throughput sequencing, assembly, and finishing, Dyadic said.